Galith Karoutchi

Biochemistry, Genetics and Molecular Biology · Life Sciences

7h-index501citations17works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Estrogen and related hormone effects(12), Protease and Inhibitor Mechanisms(4), Cancer therapeutics and mechanisms(4), Computational Drug Discovery Methods(2), Lung Cancer Treatments and Mutations(2)

Publications17 total

Supplementary Methods from AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and <i>ESR1</i>-Mutant Breast Tumors in Preclinical Models
2023Open Access
Data from AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and <i>ESR1</i>-Mutant Breast Tumors in Preclinical Models
2023Open Access
Supplementary Figure Legends from AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and <i>ESR1</i>-Mutant Breast Tumors in Preclinical Models
2023Open Access
Supplementary Methods from AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and <i>ESR1</i>-Mutant Breast Tumors in Preclinical Models
2023Open Access
Supplementary Figure Legends from AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and <i>ESR1</i>-Mutant Breast Tumors in Preclinical Models
2023Open Access
Supplementary Tables and Legends from AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and <i>ESR1</i>-Mutant Breast Tumors in Preclinical Models
2023Open Access
Supplementary Figures from AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and <i>ESR1</i>-Mutant Breast Tumors in Preclinical Models
2023Open Access
Supplementary Tables and Legends from AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and <i>ESR1</i>-Mutant Breast Tumors in Preclinical Models
2023Open Access
Data from AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and <i>ESR1</i>-Mutant Breast Tumors in Preclinical Models
2023Open Access
Supplementary Figures from AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and <i>ESR1</i>-Mutant Breast Tumors in Preclinical Models
2023Open Access
AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and <i>ESR1</i> -Mutant Breast Tumors in Preclinical Models
Cancer Research·2016· 174 cited
Optimization of a Novel Binding Motif to (<i>E</i>)-3-(3,5-Difluoro-4-((1<i>R</i>,3<i>R</i>)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1<i>H</i>-pyrido[3,4-<i>b</i>]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist
Journal of Medicinal Chemistry·2015· 159 citedOpen Access
Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2
Bioorganic & Medicinal Chemistry Letters·2011· 14 citedOpen Access
Selective non zinc binding inhibitors of MMP13
Bioorganic & Medicinal Chemistry Letters·2011· 21 citedOpen Access
Design of selective Cathepsin inhibitors
Bioorganic & Medicinal Chemistry Letters·2009· 33 citedOpen Access
Dipeptidyl nitrile inhibitors of Cathepsin L
Bioorganic & Medicinal Chemistry Letters·2009· 67 citedOpen Access
Imidazole piperazines: SAR and development of a potent class of cyclin-dependent kinase inhibitors with a novel binding mode
Bioorganic & Medicinal Chemistry Letters·2008· 33 citedOpen Access

Frequent Co-authors

Chris De Savi(14), Hazel M. Weir(13), Philip A. MacFaul(13), Robert H. Bradbury(12), Alfred A. Rabow(12), David Buttar(12), Rowena Callis(12), Jon Curwen(12), Peter Ballard(12), Craig S. Donald(12), Richard A. Norman(12), Stuart E. Pearson(12), Michael Tonge(12), Graeme E. Walker(12), Zena Wilson(12), Mandy Lawson(11), Michael Hulse(11), Rachel Rowlinson(11), Steve Powell(11), C Sadler(11)